|8.90||+0.0200||+0.23%||Vol 107.79K||1Y Perf 34.90%|
|Apr 9th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||14.75||Analyst Rating||Strong Buy 1.00|
|Potential %||65.73||Finscreener Ranking||★★★★★ 59.91|
|Insiders Trans % 3/6/12 mo.||-/-100/-100||Value Ranking||★★+ 49.97|
|Insiders Value % 3/6/12 mo.||-/-100/-100||Growth Ranking||★★★★ 62.85|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-100||Income Ranking||— -|
|Market Cap||385.05M||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||38.39||Earnings Date||4th May 2021|
Today's Price Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th May 2021|
|Estimated EPS Next Report||-0.03|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||142.23K|
|Avg. Monthly Volume||268.39K|
|Avg. Quarterly Volume||348.21K|
CytoSorbents Corporation (NASDAQ: CTSO) stock closed at 8.9 per share at the end of the most recent trading day (a 0.23% change compared to the prior day closing price) with a volume of 107.81K shares and market capitalization of 385.05M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 156 people. CytoSorbents Corporation CEO is Phillip P. Chan.
The one-year performance of CytoSorbents Corporation stock is 34.9%, while year-to-date (YTD) performance is 11.67%. CTSO stock has a five-year performance of 117.07%. Its 52-week range is between 7.13 and 11.74, which gives CTSO stock a 52-week price range ratio of 38.39%
CytoSorbents Corporation currently has a PE ratio of -, a price-to-book (PB) ratio of 63.48, a price-to-sale (PS) ratio of 11.76, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -13.09%, a ROC of -16.84% and a ROE of -18.90%. The company’s profit margin is -12.79%, its EBITDA margin is -28.50%, and its revenue ttm is $32.30 Million , which makes it $0.75 revenue per share.
Of the last four earnings reports from CytoSorbents Corporation, there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.03 for the next earnings report. CytoSorbents Corporation’s next earnings report date is 04th May 2021.
The consensus rating of Wall Street analysts for CytoSorbents Corporation is Strong Buy (1), with a target price of $14.75, which is +65.73% compared to the current price. The earnings rating for CytoSorbents Corporation stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
CytoSorbents Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
CytoSorbents Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 23.68, ATR14 : 0.60, CCI20 : -101.80, Chaikin Money Flow : -0.09, MACD : -0.41, Money Flow Index : 31.16, ROC : -16.59, RSI : 36.08, STOCH (14,3) : 27.93, STOCH RSI : 0.75, UO : 43.82, Williams %R : -72.07), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of CytoSorbents Corporation in the last 12-months were: Al W. Kraus (Option Excercise at a value of $27 600), Al W. Kraus (Sold 8 000 shares of value $64 000 ), Edward R. Jones (Option Excercise at a value of $26 800), Kathleen P. Bloch (Option Excercise at a value of $56 000), Phillip P. Chan (Option Excercise at a value of $264 798), Vincent Capponi (Option Excercise at a value of $244 978), Vincent Capponi (Sold 20 000 shares of value $200 000 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.